期刊文献+

利伐沙班治疗91例75岁以上房颤发生出血19例之分析 被引量:5

Analysis of rivaroxaban caused 19 patients with bleeding in treating 91 patients aged over 75 years with atrial fibrillation
下载PDF
导出
摘要 目的探讨75岁以上老年非瓣膜房颤病人服用利伐沙班诱发出血不良反应发生情况并分析影响因素。方法回顾性分析南京医科大学附属老年医院2018年6月至2020年3月使用利伐沙班的91例临床基本特征,如年龄、出血史、基础疾病、肝肾功能、凝血指标及合并用药等。通过方差分析和多因素logistics回归分析考察出血相关不良反应的影响因素。结果91例病例中发生出血相关不良反应的有19例(20.88%)。方差分析结果显示卒中病史、恶性肿瘤病史、既往出血史、房颤血栓栓塞风险评分(CHA2DS2-VASc评分)、抗凝出血危险评估(HAS-BLED评分)和联用选择性5-羟色胺再摄取抑制剂(SSRIs)是利伐沙班相关出血的影响因素。多因素logistic回归分析显示恶性肿瘤病史(P=0.029,OR=1.530,95%CI:1.348~284.904)和既往出血史(P=0.021,OR=9.318,95%CI:1.397~62.154),合用SSRIs(P=0.004,OR=49.502,95%CI:3.492~701.806)是出血的独立预测因子。结论75岁以上老年房颤病人既往有出血史、恶性肿瘤、合用SSRIs时服用利伐沙班应注意出血不良反应的发生。 Objective To explore the incidence of rivaroxaban caused bleeding in patients aged over 75 years with non-valvular atrial fibrillation,and to analyze the influencing factors.Methods The cases of 91 patients who had atrial fibrillation in Geriatric Hospital of Nanjing Medical University from June 2018 to March 2020 were selected as the research object,and the clinical basic characteristics of patients were recorded,such as gender,age,weight,bleeding history,underlying diseases,liver and kidney function,coagulation indicators and combined medication.The influencing factors of bleeding-related adverse reactions were investigated by variance analysis and multivariate logistics regression analysis.Results history of stroke,malignant tumor,past bleeding history,CHA2 DS2-VASC score,HAS-BLED score and combined selective serotonin reuptake inhibitors(SSRIs)were influential factors for rivaroxaban-related bleeding.Multivariate Logistic regression analysis showed that history of malignancy[P=0.029,OR=1.530,95%CI(1.348,284.904)]and bleeding history[P=0.021,OR=9.318,95%CI(1.397,62.154)],and combined with SSRIs[P=0.004,OR=49.502,95%CI(3.492,701.806)]were independent predictors of bleeding.Conclusion Patients aged over 75 years with atrial fibrillation have a history of bleeding,malignant tumors and combination with SSRIs,they should be paid attention to the occurrence of bleeding adverse reactions when taking rivaroxaban.
作者 智俊娜 曲国红 谈震 ZHI Junna;QU Guohong;TAN Zhen(Department of Pharmacy,Geriatric Hospital of Nanjing Medical University/Jiangsu Province Official Hospital,Nanjing,Jiangsu 210024,China)
出处 《安徽医药》 CAS 2021年第7期1480-1484,共5页 Anhui Medical and Pharmaceutical Journal
基金 江苏省药学会-奥赛康临床药学基金(A201710) 南京药学会-常州四药医院药学科研基金(2017YX016)。
关键词 心房颤动 利伐沙班 出血 药物相关性副作用和不良反应 老年人 Atrial fibrillation Rivaroxaban Hemorrhage Drug-related side effects and adverse reactions Aged
  • 相关文献

参考文献4

二级参考文献55

  • 1杨延宗,黄从新,高连君,刘少稳,杨东辉,林治湖.阵发性心房颤动大静脉电隔离后肌袖内自发电活动的特点[J].中华心律失常学杂志,2004,8(3):146-150. 被引量:20
  • 2周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1397
  • 3LIUJie,HUANGCong-xin,BAOMing-wei,WANGTeng.Ectopic activity induced by elevated atrial pressure in rabbit pulmonary vein in vitro[J].Chinese Medical Journal,2005(14):1210-1213. 被引量:12
  • 4龙德勇,刘兴鹏,马长生,董建增,赵文度,方冬平.心房颤动射频消融术中应用丙泊酚深度镇静的临床观察[J].中华心律失常学杂志,2006,10(5):338-341. 被引量:14
  • 5Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as anindependent risk factor for stroke : the Framingham Study. Stroke,1991,22:983-988.
  • 6Xu G, Liu X,Wu W, et al. Recurrence after ischemic stroke inChinese patients : impact of uncontrolled modifiable risk factors.Cerebrovasc Dis,2007 ,23 : 117-120.
  • 7Lansberg MG, O'Donnell MJ, Khatri P,et al. Antithrombotic andthrombolytic therapy for ischemic stroke : Antithrombotic Therapyand Prevention of Thrombosis, 9th ed : American College of ChestPhysicians Evidence-Based Clinical Practice Guidelines. Chest,2012,141(2 Suppl) : e601S-636S.
  • 8Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update ofthe ESC Guidelines for the management of atrial fibrillation : anupdate of the 2010 ESC Guidelines for the management of atrialfibrillation-developed with the special contribution of the EuropeanHeart Rhythm Association. Europace, 2012 ,14 : 1385-1413.
  • 9McCart GM, Kayser SR. Therapeutic equivalency of low-molecular-weight heparins. Ann Pharmacother, 2002 , 36: 1042-1057.
  • 10Ieko M , Tarumi T, Takeda M, et al. Synthetic selective inhibitorsof coagulation factor X a strongly inhibit thrombin generationwithout affecting initial thrombin forming time necessary for plateletactivation in hemostasis. J Thromb Haemost, 2004,2:612-618.

共引文献798

同被引文献51

引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部